ECSP22064620A - COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEINA SPIKE DEL SARS-CoV-2 - Google Patents

COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEINA SPIKE DEL SARS-CoV-2

Info

Publication number
ECSP22064620A
ECSP22064620A ECSENADI202264620A ECDI202264620A ECSP22064620A EC SP22064620 A ECSP22064620 A EC SP22064620A EC SENADI202264620 A ECSENADI202264620 A EC SENADI202264620A EC DI202264620 A ECDI202264620 A EC DI202264620A EC SP22064620 A ECSP22064620 A EC SP22064620A
Authority
EC
Ecuador
Prior art keywords
cov
sars
rbd
subunit
ndv
Prior art date
Application number
ECSENADI202264620A
Other languages
English (en)
Inventor
Díaz Manolo Clemente Fernández
Mayo Katherine Ivette Calderón
Neyra Aldo Stanlee Rojas
Original Assignee
Farm Veterinarios Sac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farm Veterinarios Sac filed Critical Farm Veterinarios Sac
Publication of ECSP22064620A publication Critical patent/ECSP22064620A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención refiere a la obtención de dos vacunas vivas recombinantes o vectorizadas de NDV que expresan la subunidad S1 y RBD de la proteína S del SARS-CoV-2, que al ser aplicada por vía intranasal en modelo de animal hámster genera la producción de anticuerpos neutralizantes contra el SARS-CoV-2. La invención muestra además que estas vacunas vivas son compatibles para su uso combinado entre sí, para inducir la producción de anticuerpos neutralizantes contra el SARS-CoV-2 sin interferencia cruzada sustancial, lo que indica una sinergia entre ambas vacunas, en donde los virus recombinantes de NDV (rNDV-LS1-HN-RBD/SARS-CoV-2(SEQ ID No. 7) y rNDV-LS1-S1-F/SARS-CoV-2(SEQ ID No. 13)), logran expresar la subunidad S1 y RBD de la proteína S del SARS-CoV-2 en mamíferos.
ECSENADI202264620A 2021-01-08 2022-08-17 COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEINA SPIKE DEL SARS-CoV-2 ECSP22064620A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PE2021000033A PE20210318A1 (es) 2021-01-08 2021-01-08 Composicion inmunogenica viva recombinante que comprende el virus de la enfermedad de newcastle (ndv) que expresa la subunidad s1 y el rbd de la proteina spike del sars-cov-2

Publications (1)

Publication Number Publication Date
ECSP22064620A true ECSP22064620A (es) 2022-09-30

Family

ID=74855966

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202264620A ECSP22064620A (es) 2021-01-08 2022-08-17 COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEINA SPIKE DEL SARS-CoV-2

Country Status (7)

Country Link
AR (1) AR124522A1 (es)
BR (1) BR112022016492A2 (es)
CO (1) CO2022010353A2 (es)
EC (1) ECSP22064620A (es)
MX (1) MX2022004220A (es)
PE (1) PE20210318A1 (es)
WO (1) WO2022149058A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021011439A (es) * 2021-09-20 2023-03-21 Laboratorio Avi Mex S A De C V Vacuna recombinante contra covid-19 para producir respuesta celular en individuos con inmunidad preexistente.
CN115785284B (zh) * 2022-11-09 2026-02-06 浙江迪福润丝生物科技有限公司 一种融合蛋白hn-rbd、编码基因、重组ndv病毒载体、重组ndv病毒及其应用
WO2024174012A1 (pt) * 2023-02-24 2024-08-29 Instituto Butantan Composição imunogênica, uso da mesma e processo de obtenção de uma composição imunogênica combinada contra covid-19 e influenza sazonal

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008007056A (es) * 2005-12-02 2008-11-12 Sinai School Medicine Virus quimericos que presentan proteinas de superficie no nativas y usos de los mismos.
WO2021229270A1 (es) * 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
CN112011521A (zh) * 2020-06-15 2020-12-01 浙江迪福润丝生物科技有限公司 一种重组新城疫病毒载体新型冠状病毒疫苗候选株及其构建方法和应用

Also Published As

Publication number Publication date
WO2022149058A1 (es) 2022-07-14
MX2022004220A (es) 2022-08-08
PE20210318A1 (es) 2021-02-16
BR112022016492A2 (pt) 2023-10-31
AR124522A1 (es) 2023-04-05
CO2022010353A2 (es) 2022-08-09

Similar Documents

Publication Publication Date Title
CO2022010353A2 (es) Composición inmunogénica viva recombinante que comprende el virus de la enfermedad de newcastle (ndv) que expresa la subunidad s1 y el rbd de la proteina spike del sars-cov-2
CO2020011914A2 (es) Vacunas de nanoestructura autoensamblantes
AR065076A1 (es) Vacuna contra el papilomavirus
CO6460752A2 (es) Respuesta inmunitaria reforzada en especies aviares
PE20141482A1 (es) Vectores recombinantes de hvt que expresan antigenos de patogenos de aves y sus usos
AR090469A1 (es) Vacuna contra el virus sincicial respiratorio (rsv)
BR112023005043A2 (pt) Vacina contra covid-19 à base de piv5
CO2022012272A2 (es) Vacunas contra el coronavirus y métodos de uso
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
MX2020003591A (es) Constructos del virus recombinante no patogenico de la enfermedad de marek que codifica multiples antigenos heterologos.
AR109538A1 (es) Vacuna contra la gripe porcina
MX2023011163A (es) Formulaciones para vacuna contra coronavirus.
MX2018015756A (es) Construcciones de virus de la enfermedad de marek recombinantes no patogenicas codificadoras de antigenos del virus de la laringotraqueitis infecciosa y del virus de la enfermedad bursal infecciosa.
MX2021004907A (es) Vacuna de ibv 4/91 con proteina espicular heterologa.
MX2021012051A (es) Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos.
AR103427A1 (es) Vacuna contra la fiebre aftosa
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
MX2024006589A (es) Formulaciones de vacunas contra el coronavirus.
PE20170429A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
UY40490A (es) Vacunas de combinación para prevenir y/o tratar múltiples agentes infecciosos
UY40331A (es) Vacuna contra el coronavirus
CL2013002631A1 (es) Virus de la necrosis pancreatica infecciosa (ipnv) avirulento porque comprende proteina vp2 madura.
CL2024000820A1 (es) Vacuna recombinante contra covid-19 para producir respuesta celular en individuos con inmunidad preexistente
MX2022001430A (es) Formulaciones de vacuna contra chikungu?a.